Neurológia pre prax 2/2020

Clinical experiences in multiple sclerosis patients treated with alemtuzumab

Alemtuzumab is a humanized monoclonal antibody approved in the Czech Republic for the treatment of highly active relapsing-remitting multiple sclerosis (RRMS). The mechanism of action of alemtuzumab consists in its binding to the CD-52 molecule, present particularly on mature T – and B-lymphocytes. This bond induces cell cytolysis with lymphocyte depletion. Subsequent repopulation reduces the autoaggressive potential of the new lymphocyte population. We present two case reports of patients treated with alemtuzumab at our site – one treatment-naive patient with no previous DMD (Disease Modifying Drugs) therapy and one patient with treatment escalation due to insufficient therapeutic response to previous DMD therapy.

Keywords: multiple sclerosis, alemtuzumab, escalation therapy, malignant multiple sclerosis